董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marc N. Casper | 男 | Chairman, President and Chief Executive Officer | 58 | 3044.96万美元 | 10.95 | 2026-03-01 |
| Nelson J. Chai | 男 | Director | 60 | 36.58万美元 | 1.39 | 2026-03-01 |
| Karen S. Lynch | 女 | Director | 63 | 未披露 | 0.0076 | 2026-03-01 |
| R. Alexandra Keith | 男 | Director | 58 | 32.70万美元 | 0.21 | 2026-03-01 |
| Dion J. Weisler | 男 | Director | 58 | 35.40万美元 | 0.65 | 2026-03-01 |
| Jennifer Johnson | -- | Director | 61 | 32.58万美元 | 0.03 | 2026-03-01 |
| James C. Mullen | 男 | Director | 67 | 32.58万美元 | 0.25 | 2026-03-01 |
| Scott M. Sperling | 男 | Director | 68 | 40.65万美元 | 8.96 | 2026-03-01 |
| C. Martin Harris | 男 | Director | 69 | 33.80万美元 | 0.81 | 2026-03-01 |
| Debora L. Spar | 女 | Director | 62 | 35.33万美元 | 0.12 | 2026-03-01 |
| Tyler E. Jacks | 男 | Director | 65 | 34.58万美元 | 0.81 | 2026-03-01 |
| Ruby R. Chandy | 女 | Director | 64 | 34.08万美元 | 0.21 | 2026-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Marc N. Casper | 男 | Chairman, President and Chief Executive Officer | 58 | 3044.96万美元 | 10.95 | 2026-03-01 |
| Michel Lagarde | 男 | Executive Vice President and Chief Operating Officer | 52 | 1277.83万美元 | 1.37 | 2026-03-01 |
| Frederick M. Lowery | 男 | Executive Vice President | 55 | 852.94万美元 | 0.83 | 2026-03-01 |
| Gianluca Pettiti | -- | Executive Vice President | 47 | 1134.04万美元 | 1.38 | 2026-03-01 |
| Joseph R. Holmes | -- | Vice President and Chief Accounting Officer | 47 | 未披露 | 未持股 | 2026-03-01 |
| Lisa P. Britt | -- | Senior Vice President and Chief Human Resources Officer | 57 | 288.95万美元 | 未持股 | 2026-03-01 |
| Michael D. Shafer | -- | Executive Vice President | 57 | 未披露 | 未持股 | 2026-03-01 |
| James R. Meyer | 男 | President, Financial Operations,Senior Vice President and CFO | 46 | 未披露 | 未持股 | 2026-03-01 |
| Michael A. Boxer | 男 | Senior Vice President and General Counsel | 64 | 311.88万美元 | 未持股 | 2026-03-01 |
董事简历
中英对照 | 中文 | 英文- Marc N. Casper
-
Marc N. Casper，赛默飞世尔科技公司：董事长、总裁兼首席执行官（2020年至今）；总裁兼首席执行官（2009-2020年）；执行副总裁兼首席运营官（2008-2009年）；执行副总裁（2006-2008年）。
Marc N. Casper,Thermo Fisher Scientific Inc.:Chairman, President and CEO (2020 - Present);President and CEO (2009 - 2020);Executive VP and COO (2008 - 2009);Executive VP (2006 - 2008). - Marc N. Casper，赛默飞世尔科技公司：董事长、总裁兼首席执行官（2020年至今）；总裁兼首席执行官（2009-2020年）；执行副总裁兼首席运营官（2008-2009年）；执行副总裁（2006-2008年）。
- Marc N. Casper,Thermo Fisher Scientific Inc.:Chairman, President and CEO (2020 - Present);President and CEO (2009 - 2020);Executive VP and COO (2008 - 2009);Executive VP (2006 - 2008).
- Nelson J. Chai
-
Nelson J. Chai，2005年12月1日，被任命为NYSE Group的执行副总裁、首席财务官。2005年12月之前，他从2000年6月起，担任Archipelago的首席财务官。2000年6月加入Archipelago之前，他是Dade Behring的业务开发高级副总裁、执行委员会成员，这是医疗诊断产品行业的领先制造商。他于1997年加入Dade Behring，担任全球实地财务副总裁，负责公司所有业务运营的财务组织。
Nelson J. Chai,CFO, Uber Technologies Inc. (2018 - 2024);President and CEO, The Warranty Group (2017 - 2018). - Nelson J. Chai，2005年12月1日，被任命为NYSE Group的执行副总裁、首席财务官。2005年12月之前，他从2000年6月起，担任Archipelago的首席财务官。2000年6月加入Archipelago之前，他是Dade Behring的业务开发高级副总裁、执行委员会成员，这是医疗诊断产品行业的领先制造商。他于1997年加入Dade Behring，担任全球实地财务副总裁，负责公司所有业务运营的财务组织。
- Nelson J. Chai,CFO, Uber Technologies Inc. (2018 - 2024);President and CEO, The Warranty Group (2017 - 2018).
- Karen S. Lynch
-
Karen S. Lynch是一位经验丰富的医疗保健高管，在该行业拥有超过30年的经验。她曾担任CVS Health Corporation （NYSE： CVS）（“CVS Health”）（一家领先的健康解决方案公司）的前总裁兼首席执行官，负责领导超过30万名员工。Lynch女士的领导下，CVS健康感动的生活超过1.2亿消费者通过其卫生保健福利和药房福利管理业务，并在9000多个社区卫生的目的地在美国之前，她服务的总裁兼首席执行官CVS健康，林奇女士担任执行副总裁CVS安泰健康和总裁，在此之前，林奇女士担任安泰公司的一些高管，健康保险公司麦哲伦健康服务公司（一家医疗保健管理公司）和信诺公司（一家全球健康保险公司）。她的职业生涯始于审计公司Ernst & Young LLP的注册会计师，此前曾担任CVS Health和U.S. Bancorp的董事会成员。
Karen S. Lynch,is a seasoned health care executive who has over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE: CVS) ("CVS Health"), a leading health solutions company, where she was responsible for leading more than 300,000 employees. Under Ms. Lynch's leadership, CVS Health touched the lives of more than 120 million consumers through its health care benefits and pharmacy benefits management businesses, and presence in over 9,000 community health destinations across the U.S. Prior to her service as president and CEO of CVS Health, Ms. Lynch served as an Executive Vice President of CVS Health and President of Aetna, and prior to that, Ms. Lynch held a number of executive positions at Aetna Inc., a health insurance company, Magellan Health Services, a health care management company, and at Cigna Corporation, a global health insurance company. Ms. Lynch began her career as a Certified Public Accountant at the auditing firm Ernst & Young LLP, and has previously served as a board member of CVS Health and U.S. Bancorp. - Karen S. Lynch是一位经验丰富的医疗保健高管，在该行业拥有超过30年的经验。她曾担任CVS Health Corporation （NYSE： CVS）（“CVS Health”）（一家领先的健康解决方案公司）的前总裁兼首席执行官，负责领导超过30万名员工。Lynch女士的领导下，CVS健康感动的生活超过1.2亿消费者通过其卫生保健福利和药房福利管理业务，并在9000多个社区卫生的目的地在美国之前，她服务的总裁兼首席执行官CVS健康，林奇女士担任执行副总裁CVS安泰健康和总裁，在此之前，林奇女士担任安泰公司的一些高管，健康保险公司麦哲伦健康服务公司（一家医疗保健管理公司）和信诺公司（一家全球健康保险公司）。她的职业生涯始于审计公司Ernst & Young LLP的注册会计师，此前曾担任CVS Health和U.S. Bancorp的董事会成员。
- Karen S. Lynch,is a seasoned health care executive who has over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE: CVS) ("CVS Health"), a leading health solutions company, where she was responsible for leading more than 300,000 employees. Under Ms. Lynch's leadership, CVS Health touched the lives of more than 120 million consumers through its health care benefits and pharmacy benefits management businesses, and presence in over 9,000 community health destinations across the U.S. Prior to her service as president and CEO of CVS Health, Ms. Lynch served as an Executive Vice President of CVS Health and President of Aetna, and prior to that, Ms. Lynch held a number of executive positions at Aetna Inc., a health insurance company, Magellan Health Services, a health care management company, and at Cigna Corporation, a global health insurance company. Ms. Lynch began her career as a Certified Public Accountant at the auditing firm Ernst & Young LLP, and has previously served as a board member of CVS Health and U.S. Bancorp.
- R. Alexandra Keith
-
R. Alexandra Keith，全球护发美容部门总裁，嫁给了Christopher Keith，他是公司的长期雇员，目前担任欧洲女性护理副总裁和品牌特许经营负责人Liners的职位。他去年的总薪酬约为815000美元，包括工资、奖金、股权赠款、退休和健康福利。他的薪酬符合公司的总体薪酬原则，基于他在公司的经验、业绩和职位。
R. Alexandra Keith,Procter & Gamble Company:Chief Executive Officer, P&G Beauty (2019 - Present), and Executive Sponsor, Corporate Sustainability (2021 - Present);President, Global Hair Care and Beauty Sector (2017 - 2019);President, Global Skin and Personal Care (2014 - 2017). - R. Alexandra Keith，全球护发美容部门总裁，嫁给了Christopher Keith，他是公司的长期雇员，目前担任欧洲女性护理副总裁和品牌特许经营负责人Liners的职位。他去年的总薪酬约为815000美元，包括工资、奖金、股权赠款、退休和健康福利。他的薪酬符合公司的总体薪酬原则，基于他在公司的经验、业绩和职位。
- R. Alexandra Keith,Procter & Gamble Company:Chief Executive Officer, P&G Beauty (2019 - Present), and Executive Sponsor, Corporate Sustainability (2021 - Present);President, Global Hair Care and Beauty Sector (2017 - 2019);President, Global Skin and Personal Care (2014 - 2017).
- Dion J. Weisler
-
Dion J. Weisler， 2015年11月至2019年10月，他担任惠普公司总裁和首席执行官，惠普公司是一家计算机、打印机和相关供应技术公司。此前，他于2013年6月至2015年11月担任惠普印刷和个人系统集团的执行副总裁，并于2012年1月至2013年6月担任印刷和个人系统，亚太和日本的高级副总裁兼董事总经理。在加入惠普之前，他曾在联想集团有限公司，一家科技公司，从2007年到2011年，包括产品的副总裁兼首席运营官和移动互联网数字家庭团体从2008年1月至2011年12月副总裁和总经理，东南亚从2007年到2008年。他之前的经验还包括Telstra Corporation Limited（一家电信公司）和Acer Incorporated（一家硬件和电子公司）的管理职位。他持有澳大利亚莫纳什大学（Monash University）的应用科学计算学士学位。Weisler先生是Thermo Fisher Scientific Inc.和BHP Group的董事会成员。Weisler先生从2015年到2020年担任惠普董事会成员。
Dion J. Weisler,is a well-respected leader in the technology sector, most notably serving as President and CEO of HP, Inc., a prominent computer, printer, and related supplies technology company, from 2015 until his retirement in 2019. During his tenure at HP, he also held the position of Executive Vice President of the Printing and Personal Systems Group from 2013 to 2015 and served as Senior Vice President and Managing Director for the Printing and Personal Systems division in the Asia Pacific and Japan region from 2012 to 2013.Before his time at HP, Dion worked at Lenovo Group Ltd., a major technology company, where he held several roles, including Vice President and COO of Product and Mobile Internet Digital Home Groups from 2008 to 2011, and Vice President and General Manager for Southeast Asia from 2007 to 2008.Dion currently serves on the boards of public companies, including Thermo Fisher Scientific Inc., a manufacturer of analytical laboratory instruments, and BHP Group, a leading mining, metals, and petroleum company. He is also a notable member of the Monash Industry Council of Advisers (MICA). - Dion J. Weisler， 2015年11月至2019年10月，他担任惠普公司总裁和首席执行官，惠普公司是一家计算机、打印机和相关供应技术公司。此前，他于2013年6月至2015年11月担任惠普印刷和个人系统集团的执行副总裁，并于2012年1月至2013年6月担任印刷和个人系统，亚太和日本的高级副总裁兼董事总经理。在加入惠普之前，他曾在联想集团有限公司，一家科技公司，从2007年到2011年，包括产品的副总裁兼首席运营官和移动互联网数字家庭团体从2008年1月至2011年12月副总裁和总经理，东南亚从2007年到2008年。他之前的经验还包括Telstra Corporation Limited（一家电信公司）和Acer Incorporated（一家硬件和电子公司）的管理职位。他持有澳大利亚莫纳什大学（Monash University）的应用科学计算学士学位。Weisler先生是Thermo Fisher Scientific Inc.和BHP Group的董事会成员。Weisler先生从2015年到2020年担任惠普董事会成员。
- Dion J. Weisler,is a well-respected leader in the technology sector, most notably serving as President and CEO of HP, Inc., a prominent computer, printer, and related supplies technology company, from 2015 until his retirement in 2019. During his tenure at HP, he also held the position of Executive Vice President of the Printing and Personal Systems Group from 2013 to 2015 and served as Senior Vice President and Managing Director for the Printing and Personal Systems division in the Asia Pacific and Japan region from 2012 to 2013.Before his time at HP, Dion worked at Lenovo Group Ltd., a major technology company, where he held several roles, including Vice President and COO of Product and Mobile Internet Digital Home Groups from 2008 to 2011, and Vice President and General Manager for Southeast Asia from 2007 to 2008.Dion currently serves on the boards of public companies, including Thermo Fisher Scientific Inc., a manufacturer of analytical laboratory instruments, and BHP Group, a leading mining, metals, and petroleum company. He is also a notable member of the Monash Industry Council of Advisers (MICA).
- Jennifer Johnson
-
Jennifer Johnson，富兰克林资源公司：总裁兼首席执行官（2020年至今）；总裁兼首席运营官（2017-2020年）。
Jennifer Johnson,Franklin Resources, Inc.:President and CEO (2020 - Present);President and COO (2017 - 2020). - Jennifer Johnson，富兰克林资源公司：总裁兼首席执行官（2020年至今）；总裁兼首席运营官（2017-2020年）。
- Jennifer Johnson,Franklin Resources, Inc.:President and CEO (2020 - Present);President and COO (2017 - 2020).
- James C. Mullen
-
James C. Mullen ，他在2011年2月加入Patheon公司，担任首席执行官和董事会成员。他在2010年作为Editas Medicine, Inc.的总裁兼首席执行官退休。他在1989年加入Biogen Inc.公司。他于2002年7月被任命为Biogen Inc.的董事会主席，并于2000年被任命为首席执行官。他曾担任总裁兼首席运营官（从1999年到2000年）， 国际副总裁（从1996年到1999年），营运副总裁（从1992年到1998年），以及董事，负责设施和工程（从1989年到1992年）。2003年，他帮助领导合并拜耳基因公司和IDEC制药公司。他拥有伦斯勒理工学院的化学工程学士学位，以及维拉诺瓦大学工商管理学硕士学位。在过去的五年，他曾任职Biogen Inc.的董事会。他也是Rivers School的受托人。他的主要职业：Patheon 公司（合同开发和制造服务的全球供应商，涉及制药和生物技术行业，在加拿大多伦多）的首席执行官。自2004年以来，他一直担任珀金埃尔默公司的董事，以及审计委员会、薪酬和福利委员会的成员。
James C. Mullen,Editas Medicine, Inc.:Executive Chair of the Board (2022 - 2023);Chairman, President and Chief Executive Officer (2021 - 2022);Chief Executive Officer, Patheon N.V. (2011 - 2017);Chief Executive Officer, Biogen, Inc. (2000 - 2010). - James C. Mullen ，他在2011年2月加入Patheon公司，担任首席执行官和董事会成员。他在2010年作为Editas Medicine, Inc.的总裁兼首席执行官退休。他在1989年加入Biogen Inc.公司。他于2002年7月被任命为Biogen Inc.的董事会主席，并于2000年被任命为首席执行官。他曾担任总裁兼首席运营官（从1999年到2000年）， 国际副总裁（从1996年到1999年），营运副总裁（从1992年到1998年），以及董事，负责设施和工程（从1989年到1992年）。2003年，他帮助领导合并拜耳基因公司和IDEC制药公司。他拥有伦斯勒理工学院的化学工程学士学位，以及维拉诺瓦大学工商管理学硕士学位。在过去的五年，他曾任职Biogen Inc.的董事会。他也是Rivers School的受托人。他的主要职业：Patheon 公司（合同开发和制造服务的全球供应商，涉及制药和生物技术行业，在加拿大多伦多）的首席执行官。自2004年以来，他一直担任珀金埃尔默公司的董事，以及审计委员会、薪酬和福利委员会的成员。
- James C. Mullen,Editas Medicine, Inc.:Executive Chair of the Board (2022 - 2023);Chairman, President and Chief Executive Officer (2021 - 2022);Chief Executive Officer, Patheon N.V. (2011 - 2017);Chief Executive Officer, Biogen, Inc. (2000 - 2010).
- Scott M. Sperling
-
Scott M. Sperling，1994年加入私募股权公司Thomas H. Lee Partners, L.P.，是公司联合总裁。之前，他在The Aeneas Group公司担任管理合伙人超过10年，该公司是哈佛管理公司（Harvard Management Company）的私人资本公司。在此之前，他担任Boston Consulting Group的高级顾问。目前他是Thermo Fisher Scientific 公司和iHeartMedia公司的董事，iHeartMedia公司前身是CC Media Holdings, Inc.，是Thomas H. Lee Partners, L.P的投资组合公司。他也任职于Brigham & Women’s/Faulker Hospital Group和Partners Healthcare的董事会。之前，他任职于华纳音乐（Warner Music Group Corp.）以及其他许多上市和私营公司董事会。
Scott M. Sperling,Co-Chief Executive Officer, Thomas H. Lee Partners, LP (1994 - Present). - Scott M. Sperling，1994年加入私募股权公司Thomas H. Lee Partners, L.P.，是公司联合总裁。之前，他在The Aeneas Group公司担任管理合伙人超过10年，该公司是哈佛管理公司（Harvard Management Company）的私人资本公司。在此之前，他担任Boston Consulting Group的高级顾问。目前他是Thermo Fisher Scientific 公司和iHeartMedia公司的董事，iHeartMedia公司前身是CC Media Holdings, Inc.，是Thomas H. Lee Partners, L.P的投资组合公司。他也任职于Brigham & Women’s/Faulker Hospital Group和Partners Healthcare的董事会。之前，他任职于华纳音乐（Warner Music Group Corp.）以及其他许多上市和私营公司董事会。
- Scott M. Sperling,Co-Chief Executive Officer, Thomas H. Lee Partners, LP (1994 - Present).
- C. Martin Harris
-
C. Martin Harris，医学博士，自2003年以来一直是董事；被任命为Invacare首席董事，在2012年5月17日生效。Harris 博士自1996年以来一直是The Cleveland Clinic Foundation in Cleveland在俄亥俄州，克利夫兰的信息技术部门的首席信息官和主席；The Cleveland Clinic Hospital和General Internal Medicine的克利夫兰诊所的基础部门的医生。此外，自2000年以来他一直担任e-Cleveland Clinic的执行董事，这是e-health临床项目在互联网上提供的一个系列。Harris 博士是HealthStream Inc. NASDAQ, Nashville, Tennessee的董事，该公司为在美国的医疗行业提供基于互联网的培训，信息，和教育的学习和研究解决方案；并且是位于马萨诸塞州，沃尔瑟姆的Thermo Fisher Scientific Inc. （NYSE）（纽约证券交易所）的董事，该公司为研究、制造、分析，发现和诊断提供分析仪器、设备、试剂和耗材，软件和服务。Harris 博士是Sentillion Corporation的董事，一个位于马萨诸塞州安多弗的医疗软件科技公司，在2010年初被卖给微软公司（Microsoft Corporation）。
C. Martin Harris,has served as Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at The University of Texas at Austin since 2016. Dr. Harris previously served as Chief Information Officer and Chairman of the Information Technology Division of The Cleveland Clinic Foundation, a non-profit academic medical center, and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine from 1996 to 2016. Additionally, from 2000 to 2016, he was Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the internet. Prior to joining the Cleveland Clinic, Dr. Harris spent 14 years with the School of Medicine at the University of Pennsylvania. - C. Martin Harris，医学博士，自2003年以来一直是董事；被任命为Invacare首席董事，在2012年5月17日生效。Harris 博士自1996年以来一直是The Cleveland Clinic Foundation in Cleveland在俄亥俄州，克利夫兰的信息技术部门的首席信息官和主席；The Cleveland Clinic Hospital和General Internal Medicine的克利夫兰诊所的基础部门的医生。此外，自2000年以来他一直担任e-Cleveland Clinic的执行董事，这是e-health临床项目在互联网上提供的一个系列。Harris 博士是HealthStream Inc. NASDAQ, Nashville, Tennessee的董事，该公司为在美国的医疗行业提供基于互联网的培训，信息，和教育的学习和研究解决方案；并且是位于马萨诸塞州，沃尔瑟姆的Thermo Fisher Scientific Inc. （NYSE）（纽约证券交易所）的董事，该公司为研究、制造、分析，发现和诊断提供分析仪器、设备、试剂和耗材，软件和服务。Harris 博士是Sentillion Corporation的董事，一个位于马萨诸塞州安多弗的医疗软件科技公司，在2010年初被卖给微软公司（Microsoft Corporation）。
- C. Martin Harris,has served as Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at The University of Texas at Austin since 2016. Dr. Harris previously served as Chief Information Officer and Chairman of the Information Technology Division of The Cleveland Clinic Foundation, a non-profit academic medical center, and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine from 1996 to 2016. Additionally, from 2000 to 2016, he was Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the internet. Prior to joining the Cleveland Clinic, Dr. Harris spent 14 years with the School of Medicine at the University of Pennsylvania.
- Debora L. Spar
-
Debora L. Spar，2008年7月至今，担任的总裁；2005-2008，担任Harvard Business School的校长、Spangler Family工商管理教授；2005-2007，担任高级副院长、科研与教员发展部主任；2004-2005，担任高级录取副主任；1999-2004，担任商业、政府与竞争教授，及商业、政府与国际经济部主席；1995-1999，担任商业、政府与竞争副教授；1991-1995，担任商业、政府与竞争助理教授。
Debora L. Spar,Harvard Business School:Professor, Business Administration (2018 - Present) and Senior Associate Dean, Business in Global Society (2021 - Present);Senior Associate Dean, Harvard Business School Online (2019 - 2021). - Debora L. Spar，2008年7月至今，担任的总裁；2005-2008，担任Harvard Business School的校长、Spangler Family工商管理教授；2005-2007，担任高级副院长、科研与教员发展部主任；2004-2005，担任高级录取副主任；1999-2004，担任商业、政府与竞争教授，及商业、政府与国际经济部主席；1995-1999，担任商业、政府与竞争副教授；1991-1995，担任商业、政府与竞争助理教授。
- Debora L. Spar,Harvard Business School:Professor, Business Administration (2018 - Present) and Senior Associate Dean, Business in Global Society (2021 - Present);Senior Associate Dean, Harvard Business School Online (2019 - 2021).
- Tyler E. Jacks
-
Tyler E. Jacks， 1992年加入麻省理工学院，现任戴维H科赫生物学教授和戴维H科赫研究所综合癌症研究主任，该研究所汇集了生物学家和工程师。自2002年成为霍华德休斯医学研究所（一家非盈利的医疗研究组织）调查员；自2009年5月开始担任赛默飞世尔科技公司（一家生命科学供应公司）董事并担任财务委员会、科技委员会和科技顾问董事会成员。2006年成立T2生物系统公司（一家私人控股生物制药公司）；自2007年开始担任多个科技顾问董事，包括Epizyme公司（一家私人控股生物制药公司）；自2001年开始担任乐骋制药公司（一家癌症治疗公司）董事。2011年10月被任命为国际癌症顾问委员会成员，为国际癌症研究所在国际癌症计划上提供建议和帮助。从2001年到2008年担任麻省理工大学癌症研究中心董事并获得多项荣誉，包括癌症研究保罗标志奖和由美国协会颁发的癌症研究杰出成就奖。2009年他被选为美国国家科学院以及美国医学研究所成员。
Tyler E. Jacks,joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology, a position he has held since 2007, and founding director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, having served as director from 2007 to 2021. Since 2021, Dr. Jacks has served as President and director of Break Through Cancer, a foundation bringing together multidisciplinary cancer research teams selected from across five participating institutions.(1) Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 1994 until 2021.Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving as the Chair of its Science and Technology Committee and as a member of its Strategy and Finance Committee and its scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks served on the scientific advisory boards of SQZ Biotechnologies Company, a biotechnology company, from 2015 until 2023, and Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately held biopharmaceutical company, and serves as the Chair of its scientific advisory board. Dr. Jacks has served as Vice Chair of the Executive Committee of the Harvard University Board of Overseers since September 2024. In 2011, he was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, and served as Chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco. - Tyler E. Jacks， 1992年加入麻省理工学院，现任戴维H科赫生物学教授和戴维H科赫研究所综合癌症研究主任，该研究所汇集了生物学家和工程师。自2002年成为霍华德休斯医学研究所（一家非盈利的医疗研究组织）调查员；自2009年5月开始担任赛默飞世尔科技公司（一家生命科学供应公司）董事并担任财务委员会、科技委员会和科技顾问董事会成员。2006年成立T2生物系统公司（一家私人控股生物制药公司）；自2007年开始担任多个科技顾问董事，包括Epizyme公司（一家私人控股生物制药公司）；自2001年开始担任乐骋制药公司（一家癌症治疗公司）董事。2011年10月被任命为国际癌症顾问委员会成员，为国际癌症研究所在国际癌症计划上提供建议和帮助。从2001年到2008年担任麻省理工大学癌症研究中心董事并获得多项荣誉，包括癌症研究保罗标志奖和由美国协会颁发的癌症研究杰出成就奖。2009年他被选为美国国家科学院以及美国医学研究所成员。
- Tyler E. Jacks,joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology, a position he has held since 2007, and founding director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, having served as director from 2007 to 2021. Since 2021, Dr. Jacks has served as President and director of Break Through Cancer, a foundation bringing together multidisciplinary cancer research teams selected from across five participating institutions.(1) Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 1994 until 2021.Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving as the Chair of its Science and Technology Committee and as a member of its Strategy and Finance Committee and its scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks served on the scientific advisory boards of SQZ Biotechnologies Company, a biotechnology company, from 2015 until 2023, and Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately held biopharmaceutical company, and serves as the Chair of its scientific advisory board. Dr. Jacks has served as Vice Chair of the Executive Committee of the Harvard University Board of Overseers since September 2024. In 2011, he was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, and served as Chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco.
- Ruby R. Chandy
-
Ruby R. Chandy，于2012年4月至2015年11月担任领先的过滤、分离、纯化技术供应商颇尔工业事业部总裁。在任职Pall之前，Chandy女士曾在几家主要的全球性公司担任领导职务，这些公司包括陶氏化学公司、罗门哈斯公司、赛默飞世尔公司和波士顿科学国际有限公司。Chandy女士目前在福斯公司和赛默飞世尔科技公司的董事会任职。Chandy女士此前曾于2013年至2022年在AMETEK，Inc.董事会任职。Chandy女士于2018年4月加入特种产品咨询委员会，并于2018年4月至2019年6月担任陶氏杜邦董事会当然成员。Chandy女士于2019年6月加入杜邦董事会。
Ruby R. Chandy,was the President of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies, from April 2012 to November 2015. Prior to her time at Pall, Ms. Chandy held leadership positions with several major, global companies including The Dow Chemical Company, Rohm and Haas Corporation, Thermo Fisher Scientific Inc. and Boston Scientific Corporation. Ms. Chandy currently serves on the boards of Flowserve Corporation and Thermo Fisher Scientific Inc. Ms. Chandy previously served on the Board of AMETEK, Inc. from 2013 to 2022. Ms. Chandy joined the Specialty Products Advisory Committee in April 2018 and served as an ex-officio member of the DowDuPont Board from April 2018 to June 2019. Ms. Chandy joined the DuPont Board of Directors in June 2019. - Ruby R. Chandy，于2012年4月至2015年11月担任领先的过滤、分离、纯化技术供应商颇尔工业事业部总裁。在任职Pall之前，Chandy女士曾在几家主要的全球性公司担任领导职务，这些公司包括陶氏化学公司、罗门哈斯公司、赛默飞世尔公司和波士顿科学国际有限公司。Chandy女士目前在福斯公司和赛默飞世尔科技公司的董事会任职。Chandy女士此前曾于2013年至2022年在AMETEK，Inc.董事会任职。Chandy女士于2018年4月加入特种产品咨询委员会，并于2018年4月至2019年6月担任陶氏杜邦董事会当然成员。Chandy女士于2019年6月加入杜邦董事会。
- Ruby R. Chandy,was the President of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies, from April 2012 to November 2015. Prior to her time at Pall, Ms. Chandy held leadership positions with several major, global companies including The Dow Chemical Company, Rohm and Haas Corporation, Thermo Fisher Scientific Inc. and Boston Scientific Corporation. Ms. Chandy currently serves on the boards of Flowserve Corporation and Thermo Fisher Scientific Inc. Ms. Chandy previously served on the Board of AMETEK, Inc. from 2013 to 2022. Ms. Chandy joined the Specialty Products Advisory Committee in April 2018 and served as an ex-officio member of the DowDuPont Board from April 2018 to June 2019. Ms. Chandy joined the DuPont Board of Directors in June 2019.
高管简历
中英对照 | 中文 | 英文- Marc N. Casper
Marc N. Casper，赛默飞世尔科技公司：董事长、总裁兼首席执行官（2020年至今）；总裁兼首席执行官（2009-2020年）；执行副总裁兼首席运营官（2008-2009年）；执行副总裁（2006-2008年）。
Marc N. Casper,Thermo Fisher Scientific Inc.:Chairman, President and CEO (2020 - Present);President and CEO (2009 - 2020);Executive VP and COO (2008 - 2009);Executive VP (2006 - 2008).- Marc N. Casper，赛默飞世尔科技公司：董事长、总裁兼首席执行官（2020年至今）；总裁兼首席执行官（2009-2020年）；执行副总裁兼首席运营官（2008-2009年）；执行副总裁（2006-2008年）。
- Marc N. Casper,Thermo Fisher Scientific Inc.:Chairman, President and CEO (2020 - Present);President and CEO (2009 - 2020);Executive VP and COO (2008 - 2009);Executive VP (2006 - 2008).
- Michel Lagarde
Michel Lagarde自2022年1月起担任Thermo Fisher Scientific Inc.（“Thermo Fisher”）的执行副总裁兼首席运营官，该公司是分析仪器、生命科学解决方案、专业诊断、实验室、制药和生物技术服务的供应商；Thermo Fisher Scientific Inc.是Vertex的供应商；Thermo Fisher Scientific Inc.的执行副总裁（2019年至2021年）；Thermo Fisher Scientific Inc.的高级副总裁兼制药服务总裁（2017年收购制药服务公司Patheon N.V。）后，Thermo Fisher Scientific Inc.于2017年加入Thermo Fisher Scientific Inc.担任高级副总裁；2008年至2016年，持有欧洲大学安特卫普工商管理学士学位，以及马斯特里赫特大学和阿姆斯特丹大学财务与控制执行硕士学位。
Michel Lagarde,Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific Inc. ("Thermo Fisher"), a supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services, since January 2022; Thermo Fisher is a supplier to Vertex;Executive Vice President at Thermo Fisher from 2019 through 2021;Senior Vice President and President, Pharma Services at Thermo Fisher from 2017 to 2019, he joining Thermo Fisher as Senior Vice President, as a result of its acquisition of Patheon N.V., a pharma services company, in 2017;President and Chief Operating Officer of Patheon N.V. from 2016 to 2017;Managing Director of JLL Partners, a private equity firm focused on healthcare, from 2008 to 2016;Holds a bachelor's degree in business administration from European University in Antwerp and an executive master's degree in finance and control from the University of Maastricht and University of Amsterdam.- Michel Lagarde自2022年1月起担任Thermo Fisher Scientific Inc.（“Thermo Fisher”）的执行副总裁兼首席运营官，该公司是分析仪器、生命科学解决方案、专业诊断、实验室、制药和生物技术服务的供应商；Thermo Fisher Scientific Inc.是Vertex的供应商；Thermo Fisher Scientific Inc.的执行副总裁（2019年至2021年）；Thermo Fisher Scientific Inc.的高级副总裁兼制药服务总裁（2017年收购制药服务公司Patheon N.V。）后，Thermo Fisher Scientific Inc.于2017年加入Thermo Fisher Scientific Inc.担任高级副总裁；2008年至2016年，持有欧洲大学安特卫普工商管理学士学位，以及马斯特里赫特大学和阿姆斯特丹大学财务与控制执行硕士学位。
- Michel Lagarde,Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific Inc. ("Thermo Fisher"), a supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services, since January 2022; Thermo Fisher is a supplier to Vertex;Executive Vice President at Thermo Fisher from 2019 through 2021;Senior Vice President and President, Pharma Services at Thermo Fisher from 2017 to 2019, he joining Thermo Fisher as Senior Vice President, as a result of its acquisition of Patheon N.V., a pharma services company, in 2017;President and Chief Operating Officer of Patheon N.V. from 2016 to 2017;Managing Director of JLL Partners, a private equity firm focused on healthcare, from 2008 to 2016;Holds a bachelor's degree in business administration from European University in Antwerp and an executive master's degree in finance and control from the University of Maastricht and University of Amsterdam.
- Frederick M. Lowery
Frederick M. Lowery自2017年起担任Thermo Fisher Scientific Inc.Thermo Fischer的高级副总裁兼生命科学解决方案和实验室产品总裁。Thermo Fischer是一家为生命科学、医疗保健和应用市场提供产品和服务的上市供应商。在他的职位上，Lowery先生领导生物生产、实验室产品和实验室化学品业务，以及生命科学解决方案的几个职能部门。自2005年加入赛默飞世尔公司以来，他曾担任多个企业的高级领导职位。在加入赛默飞世尔公司之前，Lowery先生于1999年至2005年在Maytag Corporation工作，并在通用汽车公司担任工程师。Lowery先生是波士顿复兴特许公立学校董事会成员和田纳西理工大学基金会董事会成员。Lowery先生于2019年6月加入杜邦董事会。
Frederick M. Lowery,has served as Executive Vice President and President, Laboratory Products and BioProduction, of Thermo Fisher Scientific Inc. since April 2024. Since joining Thermo Fisher in 2005, he has held several senior leadership positions across Thermo Fisher, including previously serving as President, Life Sciences Solutions and Laboratory Products, and Senior Vice President and President, Customer Channels from 2021 to 2024. Prior to his time at Thermo Fisher, Mr. Lowery was with Maytag Corporation from 1999 to 2005 and began his career as an engineer at General Motors Company. Mr. Lowery is a member of the Board of Trustees for Boston Medical Center. He is also on the Board of Trustees for both Tennessee Tech and its Foundation. Mr. Lowery joined the DuPont Board of Directors in June 2019.- Frederick M. Lowery自2017年起担任Thermo Fisher Scientific Inc.Thermo Fischer的高级副总裁兼生命科学解决方案和实验室产品总裁。Thermo Fischer是一家为生命科学、医疗保健和应用市场提供产品和服务的上市供应商。在他的职位上，Lowery先生领导生物生产、实验室产品和实验室化学品业务，以及生命科学解决方案的几个职能部门。自2005年加入赛默飞世尔公司以来，他曾担任多个企业的高级领导职位。在加入赛默飞世尔公司之前，Lowery先生于1999年至2005年在Maytag Corporation工作，并在通用汽车公司担任工程师。Lowery先生是波士顿复兴特许公立学校董事会成员和田纳西理工大学基金会董事会成员。Lowery先生于2019年6月加入杜邦董事会。
- Frederick M. Lowery,has served as Executive Vice President and President, Laboratory Products and BioProduction, of Thermo Fisher Scientific Inc. since April 2024. Since joining Thermo Fisher in 2005, he has held several senior leadership positions across Thermo Fisher, including previously serving as President, Life Sciences Solutions and Laboratory Products, and Senior Vice President and President, Customer Channels from 2021 to 2024. Prior to his time at Thermo Fisher, Mr. Lowery was with Maytag Corporation from 1999 to 2005 and began his career as an engineer at General Motors Company. Mr. Lowery is a member of the Board of Trustees for Boston Medical Center. He is also on the Board of Trustees for both Tennessee Tech and its Foundation. Mr. Lowery joined the DuPont Board of Directors in June 2019.
- Gianluca Pettiti
Gianluca Pettiti，2021年执行副总裁兼2019-2021年专业诊断副总裁兼总裁。生物科学总裁（2018-2019）。中国区总裁（2015-2017）。
Gianluca Pettiti,Executive Vice President (2021), Senior Vice President and President, Specialty Diagnostics (2019-2021), President, Biosciences (2018-2019), .- Gianluca Pettiti，2021年执行副总裁兼2019-2021年专业诊断副总裁兼总裁。生物科学总裁（2018-2019）。中国区总裁（2015-2017）。
- Gianluca Pettiti,Executive Vice President (2021), Senior Vice President and President, Specialty Diagnostics (2019-2021), President, Biosciences (2018-2019), .
- Joseph R. Holmes
Joseph R. Holmes，副总裁兼首席会计官——2021年技术会计总监，2017-2021年。
Joseph R. Holmes,Vice President and Chief Accounting Officer (2021), Senior Director, Technical Accounting (2017-2021).- Joseph R. Holmes，副总裁兼首席会计官——2021年技术会计总监，2017-2021年。
- Joseph R. Holmes,Vice President and Chief Accounting Officer (2021), Senior Director, Technical Accounting (2017-2021).
- Lisa P. Britt
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Michael D. Shafer
Michael D. Shafer，高级副总裁兼制药服务总裁（2019-2024年），材料和结构分析总裁（2016-2019年）。
Michael D. Shafer,Senior Vice President and President, Pharma Services (2019-2024),President, Materials and Structural Analysis (2016-2019).- Michael D. Shafer，高级副总裁兼制药服务总裁（2019-2024年），材料和结构分析总裁（2016-2019年）。
- Michael D. Shafer,Senior Vice President and President, Pharma Services (2019-2024),President, Materials and Structural Analysis (2016-2019).
- James R. Meyer
James R. Meyer，于2009年7月加入赛默飞世尔，曾在整个公司担任过多个责任越来越大的财务职务，包括在2020年4月至2022年12月期间担任客户渠道财务副总裁，之后于2023年1月担任现职。在加入赛默飞世尔之前，Meyer先生曾任职于普华永道。
James R. Meyer,joined Thermo Fisher in July 2009 and has served in a number of finance roles of increasing responsibility across the Company, including as Vice President of Finance, Customer Channels from April 2020 to December 2022, before assuming his current role in January 2023. Prior to joining Thermo Fisher, Mr. Meyer worked for PricewaterhouseCoopers.- James R. Meyer，于2009年7月加入赛默飞世尔，曾在整个公司担任过多个责任越来越大的财务职务，包括在2020年4月至2022年12月期间担任客户渠道财务副总裁，之后于2023年1月担任现职。在加入赛默飞世尔之前，Meyer先生曾任职于普华永道。
- James R. Meyer,joined Thermo Fisher in July 2009 and has served in a number of finance roles of increasing responsibility across the Company, including as Vice President of Finance, Customer Channels from April 2020 to December 2022, before assuming his current role in January 2023. Prior to joining Thermo Fisher, Mr. Meyer worked for PricewaterhouseCoopers.
- Michael A. Boxer
Michael A. Boxer，他于2011年4月担任执行副总裁和集团法律总顾问，负责管理集团及其全球子公司的所有法律和国际事务。自2005年9月至2011年4月，他担任高级副总裁和北美洲的法律总顾问，负责监管公司在北美洲零售业务和批发业务的所有法律事务。于1993年进入Luxottica Group S.P.A。始，他担任了多个高管职务。在于1993年进入Luxottica公司前，他在纽约的Winston & Strawn律师事务所担任企业律师。他在哥伦比亚大学（Columbia University）获得本科学位，并在纽约大学法学院（New York University School of Law）获得法学学位。
Michael A. Boxer,Senior Vice President and General Counsel (2018), Senior Vice President, General Counsel and Secretary (2021-2022), Executive Vice President and Group General Counsel, Luxottica Group S.p.A. (2011-2017).- Michael A. Boxer，他于2011年4月担任执行副总裁和集团法律总顾问，负责管理集团及其全球子公司的所有法律和国际事务。自2005年9月至2011年4月，他担任高级副总裁和北美洲的法律总顾问，负责监管公司在北美洲零售业务和批发业务的所有法律事务。于1993年进入Luxottica Group S.P.A。始，他担任了多个高管职务。在于1993年进入Luxottica公司前，他在纽约的Winston & Strawn律师事务所担任企业律师。他在哥伦比亚大学（Columbia University）获得本科学位，并在纽约大学法学院（New York University School of Law）获得法学学位。
- Michael A. Boxer,Senior Vice President and General Counsel (2018), Senior Vice President, General Counsel and Secretary (2021-2022), Executive Vice President and Group General Counsel, Luxottica Group S.p.A. (2011-2017).